Tocilizumab monotherapy and adalimumab monotherapy go head-to-head in ra


Play all audios:

Access through your institution Buy or subscribe A phase IV superiority study in patients with severe rheumatoid arthritis (RA) receiving tocilizumab or adalimumab as monotherapy (without


concomitant methotrexate) has shown that tocilizumab is superior to adalimumab for reducing the severity of disease in this setting, as now published in _The Lancet_. > ...the first study


 to specifically assess the superiority of > biologic agents from different classes as monotherapies... This is a preview of subscription content, access via your institution ACCESS


OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on


SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about


institutional subscriptions * Read our FAQs * Contact customer support ORIGINAL RESEARCH PAPER * Gabay, C. _ et al_. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of


rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. _Lancet_ doi:10.1016/S0140-6736(13)60250-0 Download references Authors * Jenny Buckland View author


publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Buckland, J. Tocilizumab


monotherapy and adalimumab monotherapy go head-to-head in RA. _Nat Rev Rheumatol_ 9, 260 (2013). https://doi.org/10.1038/nrrheum.2013.49 Download citation * Published: 09 April 2013 * Issue


Date: May 2013 * DOI: https://doi.org/10.1038/nrrheum.2013.49 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a


shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative